FY2024 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Investment analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Invivyd in a report released on Wednesday, November 20th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($1.63) per share for the year, down from their prior estimate of ($1.15). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for Invivyd’s Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at $0.15 EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.29 EPS.

Other analysts have also recently issued reports about the company. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Morgan Stanley reduced their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday.

Invivyd Trading Down 8.9 %

Shares of Invivyd stock opened at $0.70 on Friday. The business’s 50 day simple moving average is $0.97 and its 200-day simple moving average is $1.25. The stock has a market capitalization of $83.71 million, a price-to-earnings ratio of -0.36 and a beta of 0.65. Invivyd has a twelve month low of $0.70 and a twelve month high of $5.20.

Institutional Investors Weigh In On Invivyd

Large investors have recently modified their holdings of the stock. Duquesne Family Office LLC bought a new stake in Invivyd during the 2nd quarter worth approximately $629,000. Acadian Asset Management LLC raised its stake in Invivyd by 232.0% during the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after buying an additional 474,301 shares during the period. Renaissance Technologies LLC acquired a new stake in Invivyd during the 2nd quarter worth $421,000. Bank of New York Mellon Corp acquired a new stake in Invivyd during the 2nd quarter worth $263,000. Finally, Dimension Capital Management LLC increased its holdings in Invivyd by 243.3% during the 2nd quarter. Dimension Capital Management LLC now owns 189,871 shares of the company’s stock worth $209,000 after purchasing an additional 134,571 shares in the last quarter. 70.36% of the stock is currently owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.